BTOG 2021 | BTOG 2021 highlights: translational research in lung cancer
Jarushka Naidoo, MBBCh, MHS, Beaumont Hospital, Dublin, Ireland, shares an update on translational research from BTOG 2021, in particular talking on antibody drug conjugates and the targeting of KRAS in lung cancer treatment. Dr Naidoo outlines the use of sotorasib and adagrasib, both of which target KRAS G12C-mutant lung cancer. Dr Naidoo also gives an overview of the use of cellular therapies in the treatment of lung cancer, describing tumor infiltrating lymphocyte (TIL) therapy. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Jarushka Naidoo, MBBCh, MHS, has received research funding from AstraZeneca and Merck; has participated in a consultancy role or advisory board for AstraZeneca, Merck, BMS, Takeda, Pfizer, Roche/Genentech, and Daiichi Sankyo; and has received honoraria from AstraZeneca, Merck, BMS, Takeda, Pfizer, Roche/Genentech and Daiichi Sankyo.
